The tech sector was hit with selling pressure and volatility this week despite lower oil prices and yields, as money continued to flow toward other corners of the market. The S&P 500 Equal Weight (SPXEW), Dow Jones Industrial Average ($DJI), and Russell 2000 (RUT) are on track for modest weekly gains, while the Nasdaq Composite ($COMP) and cap-weighted S&P 500 (SPX) are down roughly 2% and 4% respectively. That divergence comes down to a combination of selling in the tech complex and capital rotating into non-tech areas.

One catalyst was a 10% overnight drop in the Korea Composite Stock Price Index (KOSPI) on Tuesday, an index dominated by memory giants SK Hynix and Samsung Electronics. Reports tied the swift move to deleveraging of speculative positions. U.S. margin debt hit a record $1.42T in May in nominal terms, and year-over-year growth was recently reported at more than 50% — a pace not seen since 2007, which some read as a sign of speculative excess.

Apple announced a price increase of $200 or more across its Mac and iPad lines, and the stock is on track to finish down around 5% on the week. The rest of the “Mag 7” came under pressure as well, which explains much of the SPX vs. SPXEW gap. Elsewhere, oil is on track to fall nearly 10% (WTI crude last around $69/barrel), which pulled back both yields and Fed rate-cut expectations. The PHLX Semiconductor Index (SOX) is testing support at its 20-day SMA.

The central question is whether these Mag 7 selloffs mean money is leaving the asset class or simply finding somewhere else to slosh around. Liz Ann Sonders of Schwab leans toward the optimistic read, describing a “stealth” small-cap rally and pointing out that leadership has shown up in health and biotech, not just the core AI trade — evidence, in her view, that rotation can find its way into other segments even with an overarching innovation theme intact. She ties some of the Mag 7 underperformance to capital being diverted into a heavy IPO calendar, and notes that while retail has pulled back at the individual-stock level, it remains a sizable buyer of tech overall.

Jeff DeGraff of Renaissance Macro frames the rotation as outright healthy, driven by rising real rates pushing money out of long-duration tech and into healthcare and banks. He calls the small-cap move an “incredulous advance” — one few believe in or even notice, which in his experience tends to have durability. He sees the biotech breakout in only the “top of the third inning” and views healthcare as a natural additive when tech comes under pressure, a yin-and-yang that can keep the broader market going even if mega-cap tech stays soft.

Michael Santoli acknowledges the broadening is “putting points on the board” — equal weight outperforming the cap-weighted index by several points month-to-date and sitting near a record high — but calls it delicate, since the tape is now relying on multiple other parts of the market to keep the S&P in the game. He notes rates probably still have to ease back for this value-over-growth activity to be sustained, and flags that the Russell reconstitution is already hitting the more speculative, AI-levered names at the top of the index (Credo, IonQ).

There’s a more cautious read as well. The bullish interpretation sees genuine rotation — banks breaking out, a top forming in healthcare leadership — and takes comfort that money doesn’t appear to want to leave the asset class. The counterview is that this is simply a momentum market: what’s working is momentum in utilities, industrials, and tech, and without positive price momentum, nothing works. There’s also the added concern that once the Russell reconstitution graduates many of its current drivers, the index becomes more cyclical, more value, and more contrarian — a harder backdrop to navigate against a more hawkish Fed.

The flow picture complicates the bullish narrative. Michael Hartnett of Bank of America cited a record $9.3B outflow from tech and is watching the $60 level on the MAGS ETF — a break below, in his framing, signals risk-off for the Mag 7 into the summer. Bryn Talkington suggests renaming the group the “lads,” noting names like Microsoft down sharply on the year while the Nasdaq-100 has held up because the memory and semi names (Micron, AMD, Intel) have grown into bigger index weightings — which has left many active growth managers behind.

The real-rate backdrop ties much of this together. DeGraff argues the gold narrative is “crystallizing” — long-term inflation expectations look contained, and as real rates creep back in they lift the cost of capital and compress risk premia, which historically pulls risk down and sends money toward defensives. He extends the same logic to Bitcoin, calling it one of the worst charts out there and a likely casualty of higher real rates.

The week’s story was rotation, not exit — the Mag 7 stumbled while equal weight, the Dow, and small caps picked up the slack, with leadership broadening into healthcare and biotech. Whether that’s a healthy handoff driven by rising real rates or simply a momentum market chasing what’s working remains the open debate, complicated by a record tech outflow and the looming Russell reconstitution.

On the charts: SPX and NASDAQ slipped below their 50-day, crude and gold broke key moving-average support, the dollar hit its target near $101.80, and Bitcoin broke its February low — while the Dow and Russell printed new highs.

Next week is holiday-shortened around July 4th and brings the monthly jobs report, so volatility is likely to run higher than normal regardless of which side of this debate proves right.